Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Oct 18, 2023 1:35pm
137 Views
Post# 35689356

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA's Head of CBER wants faster approvals with SE/biomarkers

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:FDA's Head of CBER wants faster approvals with SE/biomarkers
Hey fox...the only thing is that no one knows if an offer has even been put forward and what the company would deem acceptable may be quite different from what the shareholders would accept so as a shareholder we are at the mercy of the company. Also in an earlier podcast this year matt was quoted as saying that he would like to see the panc and mbc through before handing it over so he may be the sticking point in all of this.
I do not necessarily think that an offer has been made as when they did the placement with the warrants it kinda said we can try this alone IMO only of course.
I kinda think this is a race to get this trial started asap before someone else steps in and beats us to the punch so they need to get this trial started before q1 2024 ends at the minimum.
Why it is taking so long for precision definitive agreements is beyond the scope of any of us as there has to be more going on than they are telling us or hope it to be so and that they are not being too needy.
Come on ESMO, please don't let us down
<< Previous
Bullboard Posts
Next >>